Background and Study Aim: Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease characterized by remission of disease activity. Searching for laboratory markers which are simple, sensitive, specific and non-invasive is fundamental to assess the extent of inflammation, activity of the disease, evolution and prognosis which can be used to assess response to treatment and the possibility of relapse. Our aim of the work was to investigate the diagnostic role of fecal calprotectin and serum MMP-9 in determining the activity of ulcerative colitis. Patients and Methods: 71 patients were included in the study and fecal calprotectin, serum MMP-9, ESR and CRP were measured in these patients to determine the disease activity of ulcerative colitis. Results: Fecal calprotectin concentration in the patients with active UC was significantly higher than that in inactive disease and in controls (387.21 ± 44.07 μg/g vs 103.62 ± 119.67 μg/g, 12.44 ± 3.65 μg/g, p = 0.000). Serum MMP-9 was found to be higher in patients with active UC than in patients with inactive disease (11.02 ± 5.29 vs 4.01 ± 1.72 ng/ml, p = 0.000). A significant difference was also found in the patients with active UC of mild, moderate and severe degrees. Also, strong positive correlation was found between fecal calprotectin and serum MMP-9 and the severity of the disease. The area under the curve of the receiver operating characteristics (AUCROC) was 0.949 and 0.941 for fecal calprotectin and serum MMP-9 respectively. Conclusion: Fecal calprotectin and serum MMP-9 can be used to differentiate between active and inactive forms of UC.
Introduction
Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory large bowel disease (IBD) with recurrent attacks of exacerbation. Determination of the disease activity is an essential part of clinical management [1] . Nowadays, the most accurate way to evaluate the severity of UC and extent of inflammation is colonoscopy and biopsy [2] . This procedure allows direct visualization of the large bowel, and the opportunity to take intestinal tissue samples for histopathological studies.
Unfortunately, this is invasive, limited by cost, and requires an experienced operator as well as an often impossible preparatory regimen [3] [4] . Also, inter-observer variation in endoscopic evaluation of disease activity could change clinical outcomes, and have a fundamental impact on treatment options [5] [6] .
On the other hand, patient symptoms cannot effectively reflect the extent of disease and response to treatment, nor are they a reliable index of healing of intestinal mucosa. Therefore, for evaluating the disease activity and therapeutic efficacy, a combination of monitoring symptoms with clinical, laboratory and endoscopic findings is used in routine clinical practice [7] .
The diagnosis of UC is based on clinical symptoms combined with radiological and endoscopic investigations. Employment of non-invasive biomarkers is needed. Non-invasive biomarkers have the potential to avoid invasive diagnostic tests and inhibit potential complications [8] . These biomarkers can be divided into serological and fecal categories, [9] including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count, white blood cell count, interleukin-6, tumor necrosis factor-a (TNF-a), interleukin 1-b, and anti-neutrophil cytoplasmic antibody (ANCA) [10] [11] .
Potentially, fecal markers have the advantage of possessing higher specificity for gastrointestinal diseases like IBD because the feces is in direct contact with colon mucosa and consequently contains special markers of mucosal disease [12] . Fecal calprotectin is one of these markers, it is a major protein in the neutrophilic granulocytes and the macrophages [13] , which accounts for 60% of the total protein in the cytosol fraction in these cells [14] [15] . This kind of protein can resist metabolic degradation caused by intestinal bacteria, and the protein is relatively stable in stools for up to one week at room temperature [16] . It can differentiate between patients with organic or non-organic intestinal disease, and can be useful in detecting colorectal cancer and inflammatory disorders, and can also be useful in predicting a relapse of inflammatory bowel disease [10] .
The human matrix metalloproteinases (MMPs) are a family of 24 zinc dependent endopeptidases. They are divided by domain structure and substrate preference into collagenases, gelatinases, stromelysins, and membrane type MMPs (MT-MMPs) [17] . The involvement of MMPs in inflammatory processes has been documented both in animal models with experimentally induced IBD and in intestinal cell lines as well as in cultures of inflammatory altered tissues [18] .
MMP-9 has been demonstrated to be the main metalloproteinase implicated in the development of IBD [18] [19] . Recent studies suggest that it is epitheli- 
Patients & Methods
The points from the patient's initial baseline score [21] .
Blood samples were drawn by venous puncture in a fasting state. Sera were obtained from clotted (30min, room temperature) and centrifuged (15 min, 1500 ×g) blood. Serum samples were stored at −80˚C until analysis. MMP-9 concentrations were estimated by Human ELISA Kit (abcam, United Kingdom). This assay employs an antibody specific for Human MMP9 coated on a 96-well plate.
Standards and samples are drained into the wells and MMP9 present in a sample is attached to the wells by the immobilized antibody. Then we washed the wells and we added biotinylated anti-Human MMP9 antibody. After removing unbound biotinylated antibody, HRP-conjugated streptavidin is added to the wells.
The wells are again washed, a TMB substrate solution is added to the wells and color appears in proportion to the amount of bound MMP9. The Stop Solution turns the color from blue to yellow, and the color intensity is measured at 450 nm.
The stool samples were dissolved, and 50 -100 mg of the sample was suspended with 2500 -5000 μL of the fecal extraction buffer, and was homogenized; 
Statistical Analysis
Data was analyzed using SPSS advanced statistics version 22 (SPSS Inc., Chicago, 
Results
The demographic data of the studied patients presented in Table 1 Fecal calprotectin was found to have a strong positive correlation with the degree of activity of ulcerative colitis (p = 0.000) (Figure 1 ). Serum MMP-9 varied significantly with the degree of activity of ulcerative colitis with elevated levels in more severe degrees of ulcerative colitis compared to moderate or mild degrees of severity and a significant positive correlation was found between serum MMP-9 and the degree of activity of ulcerative colitis (p = 0.000) (Figure 2 ).
On the other hand, CRP and ESR did not show significant correlation with the activity of ulcerative colitis.
The ROC curve is used to select the right cut-off point and to compare the diagnostic values of two or more diagnostic tests. The ROC analysis on the fecal calprotectin showed that a cut-off point of 240 μg/g had a 100% sensitivity and a 86.9% specificity for making a differentiation between active UC and inactive UC.
As regard to serum MMP-9, a cutoff value of 4.5 ng/ml had 100% sensitivity and a 82.6% specificity to differentiate between active and inactive UC (Figure 3 ).
Discussion
UC is a chronic, relapsing disease characterized by diffuse mucosal inflammation of the colon [22] . The precise etiology of UC is unknown; however, it is thought to be caused by an inappropriate inflammatory response to the gut contents in genetically predisposed individuals [23] [24] . The incidence and prevalence of ulcerative colitis have been increasing over time worldwide [25] .
The diagnosis of UC is based on clinical symptoms combined with radiological and endoscopic investigations. Employment of non-invasive biomarkers is needed. Non-invasive biomarkers have the potential to avoid invasive diagnostic tests and inhibit potential complications [26] . Correlation between serum MMP-9 (ng/ml) and severity of ulcerative colitis. A significant positive correlation was found between serum MMP-9 and the degree of activity of ulcerative colitis. Figure 3 . ROC curve analysis on the abilities of fecal calprotectin, serum MMP-9, CRP and ESR to differentiate between active and inactive UC. The ROC analysis on the fecal calprotectin showed that a cut-off point of 240 μg/g had a 100% sensitivity and a 86.9% specificity for making a differentiation between active UC and inactive UC. As regard to serum MMP-9, a cutoff value of 4.5 ng/ml had 100% sensitivity and a 82.6% specificity to differentiate between active and inactive UC. Expression of metalloproteinases is altered in diseases with inflammatory background [33] [34] . Many studies point to MMP-9 as a key enzyme engaged in the degradation of alimentary tract tissues in the course of IBD [18] [35] . MMP-9 is also involved in the shedding and activation of biologically active molecules, which further perpetuates pathological processes observed in IBD [35] and renders MMP-9 an interesting diagnostic and therapeutic target.
Our study results revealed that fecal calprotectin level was significantly higher in active than inactive or control group with strong positive correlation with the activity of ulcerative colitis determined by Mayo score. This was in accordance with Xiang et al. who reported that fecal calprotectin concentration in the patients with active UC was significantly higher than that in the inactive UC and in the controls [36] .
Also, we found that serum MMP-9 concentration was significantly higher in patients with active ulcerative colitis than in patients with inactive state or in the control group. Serum MMP-9 levels showed strong positive correlation with activity of ulcerative colitis. Our results agreed with Lakatos et al. who noted that serum concentrations of MMP-9 were higher in UC patients compared to controls and correlated well with the disease activity [37] . Also, in agreement with our results, Malgorzata et al. reported that MMP-9 concentrations in active UC were significantly higher not only than those detected in controls but also with respect to concentrations measured in patients with inactive forms [38] .
We found in the current study that fecal calprotectin with a cutoff value of 240 μg/g had 100% sensitivity and 86.9% specificity for differentiating active ulcerative colitis from inactive disease and that a serum MMP-9 level of 4.5 ng/ml had 100% sensitivity and 82.6% specificity to differentiate active state of ulcerative colitis from inactive disease. In conclusion, fecal calprotectin and serum MMP-9 can be useful as possible supportive markers allowing differentiation between active and inactive forms of UC.
